[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.12.79. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

December 2019 - April 2015

Decade

Year

Issue

December 2019, Vol 5, No. 12, Pages 1659-1812

Original Investigation

Association of Early Palliative Care Use With Survival and Place of Death Among Patients With Advanced Lung Cancer Receiving Care in the Veterans Health Administration

Abstract Full Text
JAMA Oncol. 2019;5(12):1702-1709. doi:10.1001/jamaoncol.2019.3105

This retrospective cohort study assesses whether the receipt of early palliative care is associated with a survival benefit among patients with advanced lung cancer receiving care in the Veterans Affairs health care system.

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Abstract Full Text
JAMA Oncol. 2019;5(12):1710-1717. doi:10.1001/jamaoncol.2019.3616

This multicenter cohort study assesses whether serial postsurgical and postchemotherapy analyses of circulating tumor DNA levels could provide a real-time indication of adjuvant therapy efficacy in patients with stage III colon cancer.

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

Abstract Full Text
open access has audio
JAMA Oncol. 2019;5(12):1718-1730. doi:10.1001/jamaoncol.2019.3323

This cost-effectiveness microsimulation modeling study estimates incremental lifetime effects, costs, and cost-effectiveness of multigene testing of all patients with breast cancer compared with selective testing based on family history or clinical criteria.

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(12):1731-1738. doi:10.1001/jamaoncol.2019.3343

This phase 2 clinical trial examines the use of nivolumab combined with bevacizumab in treatment of women with relapsed platinum-sensitive or platinum-resistant ovarian cancer.

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis

Abstract Full Text
JAMA Oncol. 2019;5(12):1739-1748. doi:10.1001/jamaoncol.2019.3541

This systematic review and meta-analysis assesses outcomes of stem cell transplantations using the haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy compared with other mismatched or matched donor transplants in adult patients with hematologic cancers.

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study

Abstract Full Text
open access has active quiz
JAMA Oncol. 2019;5(12):1749-1768. doi:10.1001/jamaoncol.2019.2996

This systematic analysis describes cancer burden for 29 cancer groups across 195 countries from 1990 through 2017 to provide data needed for cancer control planning.

Brief Report

Factors Associated With Age Disparities Among Cancer Clinical Trial Participants

Abstract Full Text
has multimedia
JAMA Oncol. 2019;5(12):1769-1773. doi:10.1001/jamaoncol.2019.2055

This study characterizes the age disparities among trial enrollees in randomized clinical trials of common cancers (breast, prostate, colorectal, and lung cancer) in US population-based median age and identifies factors associated with age imbalances.

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Abstract Full Text
has audio
JAMA Oncol. 2019;5(12):1774-1778. doi:10.1001/jamaoncol.2019.2785

This cohort study assesses the clinical outcomes of patients with cancer treated with immune checkpoint inhibitors (ICIs) who received concurrent or prior broad-spectrum antibiotic treatment to determine whether an association exists between antibiotic therapy and overall survival and response to ICIs.

Research Letter

Association Between Aspirin Use and Biliary Tract Cancer Survival

Abstract Full Text
open access
JAMA Oncol. 2019;5(12):1802-1804. doi:10.1001/jamaoncol.2019.4328

This database study analyzes the association between aspirin use and survival in patients with biliary tract cancer.

Special Communication

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer

Abstract Full Text
JAMA Oncol. 2019;5(12):1790-1798. doi:10.1001/jamaoncol.2019.4114

This special communication provides recommendations regarding the participation of patients with muscle-invasive bladder cancer in randomized clinical trials.

Review

The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature

Abstract Full Text
JAMA Oncol. 2019;5(12):1779-1789. doi:10.1001/jamaoncol.2019.3338

This systematic review qualitatively assesses the results of studies that evaluated understanding, preferences, and the value placed on the end point of progression-free survival among patients with advanced cancer.

JAMA Oncology Clinical Challenge

Subungual Mass in a Middle-aged Woman

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(12):1799-1800. doi:10.1001/jamaoncol.2019.4500

A woman in her 50s presented with a history of a painful subungual mass of the thumb that was initially believed to be an infection. What is your diagnosis?

Viewpoint

Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility—Pandora’s Box Is Opening Wider

Abstract Full Text
JAMA Oncol. 2019;5(12):1687-1688. doi:10.1001/jamaoncol.2019.4004

This Viewpoint argues that there is not yet enough evidence to support genetic testing in patients with breast cancer who do not meet current guidelines for testing.

Improving Molecular Oncology by Making Results Available to Patients

Abstract Full Text
JAMA Oncol. 2019;5(12):1689-1690. doi:10.1001/jamaoncol.2019.4390

This Viewpoint discusses why making biomarker test results available to patients can help them engage in their own care and receive appropriate targeted therapy.

A Cost-Focused Alternative Cancer Medication Dispensing Strategy—“Pack Splitting”

Abstract Full Text
JAMA Oncol. 2019;5(12):1691-1692. doi:10.1001/jamaoncol.2019.4129

This Viewpoint argues that using a pack-splitting strategy for dispensing drugs that are sold in blister card packages can yield substantial cost savings for some expensive drugs.

Editorial

Prolonged Survival With Palliative Care—It Is Possible, but Is It Necessary?

Abstract Full Text
JAMA Oncol. 2019;5(12):1693-1694. doi:10.1001/jamaoncol.2019.3100

Crafting a JAMA Oncology Clinical Challenge

Abstract Full Text
free access
JAMA Oncol. 2019;5(12):1695. doi:10.1001/jamaoncol.2019.4001

Is the Patient Cured?

Abstract Full Text
JAMA Oncol. 2019;5(12):1695-1697. doi:10.1001/jamaoncol.2019.3612
Cancer Care Chronicles

Insights From a Patient With Lung Cancer—Party Therapy Is Way Better Than Chemotherapy

Abstract Full Text
JAMA Oncol. 2019;5(12):1685-1686. doi:10.1001/jamaoncol.2019.2591

This essay describes the wisdom and insights gained while treating a woman with metastatic lung cancer.

Poetry and Oncology

DNA

Abstract Full Text
JAMA Oncol. 2019;5(12):1812. doi:10.1001/jamaoncol.2019.3121
Comment & Response

Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View

Abstract Full Text
JAMA Oncol. 2019;5(12):1804-1805. doi:10.1001/jamaoncol.2019.4049

Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(12):1805. doi:10.1001/jamaoncol.2019.4055

Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma

Abstract Full Text
JAMA Oncol. 2019;5(12):1805-1806. doi:10.1001/jamaoncol.2019.4052

Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(12):1806-1807. doi:10.1001/jamaoncol.2019.4058

Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit

Abstract Full Text
JAMA Oncol. 2019;5(12):1807. doi:10.1001/jamaoncol.2019.4091

Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Clinical Benefit—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(12):1807-1808. doi:10.1001/jamaoncol.2019.4132

Tumor Mutation Burden—From Doubts to Concerns

Abstract Full Text
JAMA Oncol. 2019;5(12):1808-1809. doi:10.1001/jamaoncol.2019.4138

Tumor Mutation Burden—From Doubts to Concerns—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(12):1809. doi:10.1001/jamaoncol.2019.4141

Biology vs Access to Care—Relative Contribution to Racial Disparities in Prostate Cancer

Abstract Full Text
JAMA Oncol. 2019;5(12):1809-1810. doi:10.1001/jamaoncol.2019.4497

Biology vs Access to Care—Relative Contribution to Racial Disparities in Prostate Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(12):1810-1811. doi:10.1001/jamaoncol.2019.4509

Failure to Disclose Potential Conflict of Interest—Letter of Explanation

Abstract Full Text
JAMA Oncol. 2019;5(12):1811. doi:10.1001/jamaoncol.2019.5259
Correction

Failure to Disclose a Potential Conflict of Interest

Abstract Full Text
free access
JAMA Oncol. 2019;5(12):1811. doi:10.1001/jamaoncol.2019.5468

Error in the Figure

Abstract Full Text
free access
JAMA Oncol. 2019;5(12):1811. doi:10.1001/jamaoncol.2019.5657

Error in Figure 2D

Abstract Full Text
free access
JAMA Oncol. 2019;5(12):1811. doi:10.1001/jamaoncol.2019.5667
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2019;5(12):1662. doi:10.1001/jamaoncol.2018.4798
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2019;5(12):1659. doi:10.1001/jamaoncol.2018.4797
×